Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: A phase 1 trial
Last Updated: Thursday, July 10, 2025
A phase 1 trial evaluating the use of cord-blood-derived cytokine-preactivated and expanded natural killer cells precomplexed with AFM13 (AFM13-NK) to treat patients with CD30+ lymphoma refractory to brentuximab vedotin and anti-PD1 checkpoint inhibitors. The researchers concluded that the preliminary data are encouraging, warranting further investigation into this therapy.
Advertisement
News & Literature Highlights